The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity
Open accessAbstract
Summary Chimeric antigen receptors (CARs) significantly enhance anti-tumor activity of immune effector cells. While most studies have evaluated CAR-expression in T cells, here we evaluate different CAR constructs that improve natural killer (NK) cell-mediated killing. We identified a CAR containing the transmembrane domain of NKG2D, the 2B4 co-stimulatory domain, and the CD3ζ signaling domain to mediate strong antigen-specific NK cell signaling. NK cells derived from human iPSCs that express this CAR (NK-CAR-iPSC-NK cells) have a typical NK cell phenotype and demonstrate improved anti-tumor activity compared to T-CAR expressing iPSC-derived NK cells (T-CAR-iPSC-NK cells) and non-CAR expressing cells. Using an ovarian cancer xenograft model, NK-CAR-iPSC-NK cells significantly inhibited tumor growth and prolonged survival compared to PB-NK cells, iPSC-NK cells, or T-CAR-iPSC-NK cells. Additionally, NK-CAR-iPSC-NK cells demonstrate similar in vivo activity as T-CAR-expressing T cells, though with less toxicity. These NK-CAR-iPSC-NK cells now provide standardized, targeted “off the shelf” lymphocytes for anti-cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Caligiuri, M. A. (2008) · Blood · doi:10.1182/blood-2007-09-077438 · Cited by 1,905
Miller, J. S., Soignier, Y., Panoskaltsis-Mortari, A., McNearney, S. A., Yun, G. H., Fautsch, S. K., McKenna, D., Le, C., Defor, T. E., Burns, L. J., et al. (2005) · Blood · doi:10.1182/blood-2004-07-2974 · Cited by 1,903
Up on the tightrope: natural killer cell activation and inhibition
Lanier, L. L. (2008) · Nature Immunology · doi:10.1038/ni1581 · Cited by 1,656
Controlling Natural Killer Cell Responses: Integration of Signals for Activation and Inhibition
Long, E. O., Sik Kim, H., Liu, D., Peterson, M. E., & Rajagopalan, S. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075005 · Cited by 1,217
NK cells and cancer: you can teach innate cells new tricks
Morvan, M. G., & Lanier, L. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.5 · Cited by 1,162
Teachey, D. T., Lacey, S. F., Shaw, P. A., Melenhorst, J. J., Maude, S. L., Frey, N., Pequignot, E., Gonzalez, V. E., Chen, F., Finklestein, J., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0040 · Cited by 1,102
Engineered T cells: the promise and challenges of cancer immunotherapy
Fesnak, A. D., June, C. H., & Levine, B. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.97 · Cited by 1,074
Targeting natural killer cells in cancer immunotherapy
Guillerey, C., Huntington, N. D., & Smyth, M. J. (2016) · Nature Immunology · doi:10.1038/ni.3518 · Cited by 1,066
Ahmed, N., Brawley, V. S., Hegde, M., Robertson, C., Ghazi, A., Gerken, C., Liu, E., Dakhova, O., Ashoori, A., Corder, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.0225 · Cited by 1,004
Romee, R., Rosario, M., Berrien-Elliott, M. M., Wagner, J. A., Jewell, B. A., Schappe, T., Leong, J. W., Abdel-Latif, S., Schneider, S. E., Willey, S., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf2341 · Cited by 942
Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells
Qasim, W., Zhan, H., Samarasinghe, S., Adams, S., Amrolia, P., Stafford, S., Butler, K., Rivat, C., Wright, G., Somana, K., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaj2013 · Cited by 902
Beatty, G. L., Haas, A. R., Maus, M. V., Torigian, D. A., Soulen, M. C., Plesa, G., Chew, A., Zhao, Y., Levine, B. L., Albelda, S. M., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0170 · Cited by 864
Liu, E., Tong, Y., Dotti, G., Shaim, H., Savoldo, B., Mukherjee, M., Orange, J., Wan, X., Lu, X., Reynolds, A., et al. (2018) · Leukemia · doi:10.1038/leu.2017.226 · Cited by 824
Natural Killer Cell Signaling Pathways
Vivier, E., Nunès, J. A., & Vély, F. (2004) · Science · doi:10.1126/science.1103478 · Cited by 751
CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
Maude, S. L., Teachey, D. T., Porter, D. L., & Grupp, S. A. (2015) · Blood · doi:10.1182/blood-2014-12-580068 · Cited by 727
Activation of NK cell cytotoxicity
Smyth, M. J., Cretney, E., Kelly, J. M., Westwood, J. A., Street, S. E. A., Yagita, H., Takeda, K., Dommelen, S. L. H. V., Degli-Esposti, M. A., & Hayakawa, Y. (2005) · Molecular Immunology · doi:10.1016/j.molimm.2004.07.034 · Cited by 714
Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells
Denman, C. J., Senyukov, V. V., Somanchi, S. S., Phatarpekar, P. V., Kopp, L. M., Johnson, J. L., Singh, H., Hurton, L., Maiti, S. N., Huls, M. H., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030264 · Cited by 683
Imai, C., Iwamoto, S., & Campana, D. (2005) · Blood · doi:10.1182/blood-2004-12-4797 · Cited by 659
Activation, coactivation, and costimulation of resting human natural killer cells
Bryceson, Y. T., March, M. E., Ljunggren, H., & Long, E. O. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00457.x · Cited by 650
NK cell-based immunotherapy for malignant diseases
Cheng, M., Chen, Y., Xiao, W., Sun, R., & Tian, Z. (2013) · Cellular & Molecular Immunology · doi:10.1038/cmi.2013.10 · Cited by 631
Geller, M. A., Cooley, S., Judson, P. L., Ghebre, R., Carson, L. F., Argenta, P. A., Jonson, A. L., Panoskaltsis-Mortari, A., Curtsinger, J., McKenna, D., et al. (2011) · Cytotherapy · doi:10.3109/14653249.2010.515582 · Cited by 436
Bachanova, V., Cooley, S., Defor, T. E., Verneris, M. R., Zhang, B., McKenna, D. H., Curtsinger, J., Panoskaltsis-Mortari, A., Lewis, D., Hippen, K., et al. (2014) · Blood · doi:10.1182/blood-2013-10-532531 · Cited by 435
Co-association of CD3ζ with a receptor (CD16) for IgG Fc on human natural killer cells
Lanier, L. L., Yu, G., & Phillips, J. H. (1989) · Nature · doi:10.1038/342803a0 · Cited by 432
IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo
Koneru, M., Purdon, T. J., Spriggs, D., Koneru, S., & Brentjens, R. J. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.994446 · Cited by 418
Knorr, D. A., Ni, Z., Hermanson, D., Hexum, M. K., Bendzick, L., Cooper, L. J. N., Lee, D. A., & Kaufman, D. S. (2013) · Stem Cells Translational Medicine · doi:10.5966/sctm.2012-0084 · Cited by 415
Self-citationNatural Killer Cells for Immunotherapy – Advantages of the NK-92 Cell Line over Blood NK Cells
Klingemann, H., Boissel, L., & Toneguzzo, F. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00091 · Cited by 414
Xie, F., Ye, L., Chang, J. C., Beyer, A. I., Wang, J., Muench, M. O., & Kan, Y. W. (2014) · Genome Research · doi:10.1101/gr.173427.114 · Cited by 408
Promiscuity and the single receptor: NKG2D
Eagle, R. A., & Trowsdale, J. (2007) · Nature Reviews Immunology · doi:10.1038/nri2144 · Cited by 374
Negative signaling by inhibitory receptors: the NK cell paradigm
Long, E. O. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00660.x · Cited by 370
Chimeric Antigen Receptor Therapy for Cancer
Barrett, D. M., Singh, N., Porter, D. L., Grupp, S. A., & June, C. H. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-060512-150254 · Cited by 349
Mesothelin targeted cancer immunotherapy
Hassan, R., & Ho, M. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2007.08.028 · Cited by 340
Chang, Y.-H., Connolly, J., Shimasaki, N., Mimura, K., Kono, K., & Campana, D. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3558 · Cited by 329
Ng, E. S., Davis, R., Stanley, E. G., & Elefanty, A. G. (2008) · Nature Protocols · doi:10.1038/nprot.2008.42 · Cited by 325
Zhang, C., Oberoi, P., Oelsner, S., Waldmann, A., Lindner, A., Tonn, T., & Wels, W. S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00533 · Cited by 306
The insulation of genes from external enhancers and silencing chromatin
Burgess-Beusse, B., Farrell, C., Gaszner, M., Litt, M., Mutskov, V., Recillas-Targa, F., Simpson, M., West, A., & Felsenfeld, G. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162342499 · Cited by 292
Song, D.-G., Ye, Q., Carpenito, C., Poussin, M., Wang, L.-P., Ji, C., Figini, M., June, C. H., Coukos, G., & Powell, D. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0422 · Cited by 287
Sakamoto, N., Ishikawa, T., Kokura, S., Okayama, T., Oka, K., Ideno, M., Sakai, F., Kato, A., Tanabe, M., Enoki, T., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0632-8 · Cited by 270
Woll, P. S., Grzywacz, B., Tian, X., Marcus, R. K., Knorr, D. A., Verneris, M. R., & Kaufman, D. S. (2009) · Blood · doi:10.1182/blood-2008-06-165225 · Cited by 268
Self-citationDAP12-Based Activating Chimeric Antigen Receptor for NK Cell Tumor Immunotherapy
Töpfer, K., Cartellieri, M., Michen, S., Wiedemuth, R., Müller, N., Lindemann, D., Bachmann, M., Füssel, M., Schackert, G., & Temme, A. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1400330 · Cited by 249
Genetic Manipulation of NK Cells for Cancer Immunotherapy: Techniques and Clinical Implications
Carlsten, M., & Childs, R. W. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00266 · Cited by 243
Induced Pluripotent Stem Cell-Derived Natural Killer Cells for Treatment of Ovarian Cancer
Hermanson, D. L., Bendzick, L., Pribyl, L., McCullar, V., Vogel, R. I., Miller, J. S., Geller, M. A., & Kaufman, D. S. (2016) · Stem Cells · doi:10.1002/stem.2230 · Cited by 242
Self-citationActivating interactions in human NK cell recognition: the role of 2B4-CD48
Nakajima, H., Cella, M., Langen, H., Friedlein, A., & Colonna, M. (1999) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199905)29:05<1676::aid-immu1676>3.0.co;2-y · Cited by 242
NKG2D and its ligands in cancer
Dhar, P., & Wu, J. D. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.02.004 · Cited by 239
Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens
Childs, R. W., & Carlsten, M. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4506 · Cited by 236
Chowdhury, P. S., Viner, J. L., Beers, R., & Pastan, I. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.2.669 · Cited by 222
Dolstra, H., Roeven, M. W. H., Spanholtz, J., Hangalapura, B. N., Tordoir, M., Maas, F., Leenders, M., Bohme, F., Kok, N., Trilsbeek, C., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2981 · Cited by 210
Altvater, B., Landmeier, S., Pscherer, S., Temme, J., Schweer, K., Kailayangiri, S., Campana, D., Juergens, H., Pule, M., & Rossig, C. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2810 · Cited by 206
Garrity, D., Call, M. E., Feng, J., & Wucherpfennig, K. W. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502439102 · Cited by 205
ITAM-mediated Signaling by the T-Cell Antigen Receptor
Love, P. E., & Hayes, S. M. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a002485 · Cited by 196
New cell sources for T cell engineering and adoptive immunotherapy
Themeli, M., Rivière, I., & Sadelain, M. (2015) · Cell stem cell · doi:10.1016/j.stem.2015.03.011 · Cited by 179
CAR-T Cell Therapy for Lymphoma
Ramos, C. A., Heslop, H. E., & Brenner, M. K. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-051914-021702 · Cited by 173
Utilizing Chimeric Antigen Receptors to Direct Natural Killer Cell Activity
Hermanson, D. L., & Kaufman, D. S. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00195 · Cited by 172
Self-citationA Structural Basis for the Association of DAP12 with Mouse, but Not Human, NKG2D1
Rosen, D., Araki, M., Hamerman, J., Chen, T., Yamamura, T., & Lanier, L. (2004) · Journal of Immunology · doi:10.4049/jimmunol.173.4.2470 · Cited by 167
Use of Allogeneic NK Cells for Cancer Immunotherapy
Geller, M. A., & Miller, J. S. (2011) · Immunotherapy · doi:10.2217/imt.11.131 · Cited by 162
Exploitation of natural killer cells for the treatment of acute leukemia
Handgretinger, R., Lang, P., & André, M. C. (2016) · Blood · doi:10.1182/blood-2015-12-629055 · Cited by 159
Yang, Y., Lim, O., Kim, T. M., Ahn, Y., Choi, H., Chung, H., Min, B., Her, J. H., Cho, S., Keam, B., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0118 · Cited by 155
Kwon, H., Choi, G.-E., Ryu, S., Kwon, S. J., Kim, S. C., Booth, C., Nichols, K. E., & Kim, H. S. (2016) · Nature Communications · doi:10.1038/ncomms11686 · Cited by 153
Wilber, A. C., Linehan, J. L., Tian, X., Woll, P. S., Morris, J. K., Belur, L. R., McIvor, R. S., & Kaufman, D. S. (2007) · Stem Cells · doi:10.1634/stemcells.2007-0026 · Cited by 127
Self-citationGenetic Modification of Human Embryonic Stem Cells for Derivation of Target Cells
Giudice, A., & Trounson, A. O. (2008) · Cell stem cell · doi:10.1016/j.stem.2008.04.003 · Cited by 115
Bachanová, V., & Miller, J. S. (2014) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2014011091 · Cited by 115
Advances in clinical NK cell studies: Donor selection, manufacturing and quality control
Koehl, U., Kalberer, C. P., Spanholtz, J., Lee, D. A., Miller, J. S., Cooley, S., Lowdell, M. W., Uharek, L., Klingemann, H., Curti, A., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1115178 · Cited by 110
Song, D.-G., Ye, Q., Santoro, S. P., Fang, C., Best, A. J., & Powell, D. J. (2013) · Human Gene Therapy · doi:10.1089/hum.2012.143 · Cited by 108
Costimulation of Multiple NK Cell Activation Receptors by NKG2D
Ho, E. L., Carayannopoulos, L. N., Poursine‐Laurent, J., Kinder, J. M., Plougastel-Douglas, B., Smith, H. R. C., & Yokoyama, W. M. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.7.3667 · Cited by 107
Ni, Z., Knorr, D. A., Clouser, C. L., Hexum, M. K., Southern, P. J., Mansky, L. M., Park, I., & Kaufman, D. S. (2010) · Journal of Virology · doi:10.1128/jvi.01774-10 · Cited by 100
Self-citationNi, Z., Knorr, D. A., Bendzick, L. E., Allred, J. R., & Kaufman, D. S. (2013) · Stem Cells · doi:10.1002/stem.1611 · Cited by 99
Self-citationBollino, D. R., & Webb, T. J. (2017) · Translational research · doi:10.1016/j.trsl.2017.06.003 · Cited by 84
Figueroa, J. A., Reidy, A., Mirandola, L., Trotter, K., Suvorava, N., Figueroa, A., Konala, V., Aulakh, A., Littlefield, L., Grizzi, F., et al. (2015) · International Reviews of Immunology · doi:10.3109/08830185.2015.1018419 · Cited by 78
Zhang, T., & Sentman, C. L. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3200 · Cited by 65
Yahata, K., Maeshima, K., Sone, T., Ando, T., Okabe, M., Imamoto, N., & Imamoto, F. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.09.054 · Cited by 42
Modular assembly of transposon integratable multigene vectors using RecWay assembly
Moriarity, B. S., Rahrmann, E. P., Keng, V. W., Manlove, L. S., Beckmann, D. A., Wolf, N. K., Khurshid, T., Bell, J. B., & Largaespada, D. A. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt115 · Cited by 16
Self-citationBischof, A. (2000) · doi:10.1002/1521-4141(200003)30:3
Cited by
New approaches and procedures for cancer treatment: Current perspectives
Debela, D. T., Muzazu, S. G., Heraro, K. D., Ndalama, M. T., Mesele, B. W., Haile, D. C., Kitui, S. K., & Manyazewal, T. (2021) · SAGE Open Medicine · doi:10.1177/20503121211034366 · Cited by 1,597
Harnessing innate immunity in cancer therapy
Demaria, O., Cornen, S., Daëron, M., Morel, Y., Medzhitov, R., & Vivier, E. (2019) · Nature · doi:10.1038/s41586-019-1593-5 · Cited by 957
Natural killer cells in cancer biology and therapy
Wu, S.-Y., Fu, T., Jiang, Y.-Z., & Shao, Z.-M. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01238-x · Cited by 863
CAR-NK cells: A promising cellular immunotherapy for cancer
Xie, G., Dong, H., Liang, Y., Ham, J. D., Rizwan, R., & Chen, J. (2020) · eBioMedicine · doi:10.1016/j.ebiom.2020.102975 · Cited by 800
Natural killer cells in antitumour adoptive cell immunotherapy
Laskowski, T. J., Biederstädt, A., & Rezvani, K. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00491-0 · Cited by 773
Metadata
- Authors
- Li, Y., Hermanson, D. L., Moriarity, B. S., & Kaufman, D. S.
- Venue
- Cell Stem Cell
- Publisher
- Elsevier BV
- Published
- 2018-08
- Volume
- 23
- Issue
- 2
- Pages
- 181-192.e5
- ISSN
- 1875-9777 (ISSN-L)
- 1934-5909
- OpenAlex
- W2810715813
- Cited by
- 981
- References
- 73
- FWCI
- 30.33
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.